Aug 30 2023 34 mins 3
Listen as Andrew Guise gives key insight into the deal making landscape - asset value, accessing the market, positioning and the actual deal process in the current economic climate - from the unique position standing astride both the financial world and the technical world translating science into value.
About the Interviewee:
Andrew Guise is a Managing Director at PharmaVentures and is a member of the Corporate Advisory Team.
Andrew is a highly accomplished executive with a wealth of experience in finance, business development, and leadership. Notable deals including IPOs for IsoTis, Genmab and Thrombogenics, secondaries for Serono ($4bn), divestments of, St Martins Healthcare (hospitals), Degussa Dental, Synthes Stratec (ortho), Plasso to Becton Dickenson (lab supply), Oxxon to Oxford Bio (immunotherapy), Surface Therapeutics to Serentis (dermatology), Zyentia to Lonza (protein refolding). Andrew has held Board positions at Oxford Biosensors (POC diag), Oxitec (pest control), Prolysis (anti -infectives), Purity Health (reformulation), and Gaia Biotherapeutics (cannabinoids).
During his professional career Andrew has acted as advisor (SME to FTSE 100), VC investor, and held Board / C suite roles in a number of life science companies across multiple sectors. Andrew has over 30 years’ experience in all areas of healthcare. Andrew holds a BEng in Biochemical Engineering and a PhD in Protein Refolding.
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
